565-96-8

Basic information

• Product Name: 11α-Hydroxy-5α-pregnane-3,20-dione
• Synonyms: 11α-Hydroxyallopregnane-3,20-dione
• CAS NO: 565-96-8
• Molecular Formula: C₂₁H₃₂O₃
• Molecular Weight: 332.47698
• Mol File: 565-96-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 193-195 °C
• Boiling Point: 468.1°Cat760mmHg
• Flash Point: 251°C
• Appearance: /
• Density: 1.112g/cm³
• Vapor Pressure: 9.95E-11mmHg at 25°C
• Refractive Index: 1.532
• PKA: 14.66±0.70(Predicted)
• CAS DataBase Reference: 11α-Hydroxy-5α-pregnane-3,20-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 11α-Hydroxy-5α-pregnane-3,20-dione(565-96-8)
• EPA Substance Registry System: 11α-Hydroxy-5α-pregnane-3,20-dione(565-96-8)

Safety Data

• Hazardous Substances Data: 565-96-8(Hazardous Substances Data)

Usage

Uses

11α-Hydroxyallopregnane-3,20-dione is a monoform intermediate and byproduct in the transformation pathway of the progesterone by Rhizopus nigricans.

InChI:InChI=1/C21H32O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h13,15-19,24H,4-11H2,1-3H3/t13-,15-,16+,17-,18+,19+,20-,21+/m0/s1

Upstream product

• 21063-87-6 11α-hydroxypregna-4,6-diene-3,20-dione 
• 102291-06-5 3,3,20,20-Bis--5α-pregn-9(11)-en 
• 600-52-2 3α,11α-dihydroxy-5β-pregnan-20-one 
• 80-75-1 11-alpha-hydroxyprogesterone 
• 15807-38-2 20,20-ethanediyldioxy-3α-hydroxy-5β-pregnan-11-one 
• 115267-39-5 20,20-ethanediyldioxy-5β-pregnane-3α,11α-diol 
• 1162-56-7 6-dehydroprogesterone 
• 128-23-4 pregnanedione 
• 884878-03-9 11α-acetoxy-3β-hydroxy-5α-pregnan-20-one 
• 565-91-3 3β,11α-dihydroxy-5α-pregnan-20-one 
• 566-65-4 dihydroprogesterone 

Downstream Products

• 565-91-3 3β,11α-dihydroxy-5α-pregnan-20-one 
• 516-15-4 11-Ketoprogesterone 
• 600-52-2 3α,11α-dihydroxy-5β-pregnan-20-one 
• 1408057-12-4 3α-hydroxy-20-oxo-5β-pregnan-11α-yl pentafluorobenzoate 
• 1408057-14-6 20-oxo-11α-(pentafluorobenzoyl)oxy-5β-pregnan-3α-yl sulfate pyridinium salt 
• 1408057-11-3 3,20-dioxo-5β-pregnan-11α-yl pentafluorobenzoate 
• 565-99-1 UC₁₀₁₇ 
• 23930-19-0 Alphaxalone 
• 38398-44-6 3α,11α-dihydroxy-5α-pregnan-20-one 
• 565-92-4 5β-pregnan-3α,11β-diol-20-one 
• 1256911-22-4 20-oxo-5β-pregnan-3α-yl (2S)-5-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]-5-oxo-pentanoate 
• 1357077-97-4 20-oxo-5β-[9,12,12-(2)H3]pregnan-3α-yl (2S)-5-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]-5-oxo-pentanoate 
• 1064-78-4 3α,11α-dibenzoyloxy-5β-pregnan-20-one 
• 1312468-70-4 3β,11α-dibenzoyloxy-5β-pregnan-20-one 

Relevant articles and documents

NEUROACTIVE STEROIDS AND METHODS OF PREPARATION

Disclosed are neuroactive steroid anaesthetic agents, methods for their preparation and compositions comprising the same. The invention provides scaled up and/or GMP methods for preparing neuroactive steroids, such as alfaxalone, alfadolone and alfadolone acetate.

Allopregnanolone and pregnanolone analogues modified in the C ring: Synthesis and activity

(25R)-3β-Hydroxy-5α-spirostan-12-one (hecogenin) and 11α-hydroxypregn-4-ene-3,20-dione (11α-hydroxyprogesterone) were used as starting materials for the synthesis of a series of 11- and 12-substituted derivatives of 5ξ-pregnanolone (3α-hydroxy-5α- pregnan-20-one and 3α-hydroxy-5β-pregnan-20-one), the principal neurosteroid acting via γ-aminobutyric acid (GABA). These analogues were designed to study the structural requirements of the corresponding GABA A receptor. Their biological activity was measured by in vitro test with [3H]flunitrazepam as radioligand in which allopregnanolone and its active analogues stimulated the binding to the GABAA receptor. Analysis of the SAR data suggests dependence of the flunitrazepam binding activity on the hydrophobic-hydrophilic balance of the groups at the C-ring edge rather than on specific interactions between them and the receptor.

NEW STEROID INHIBITORS OF PGP FOR USE FOR INHIBITING MULTIDRUG RESISTANCE

The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.